FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a method for prediction of thromboembolic complications (VTEC) in females accompanying a prothrombin [F2(20210)GA] mutation, where prothrombin activity is determined and if its value is 174.8 % and higher, a risk of developing VTEC is predicted, wherein prothrombin activity is expressed in international units (IU) or percentage, wherein 1 IU/ml corresponds to 100 % activity.
EFFECT: invention provides higher accuracy of prediction of thrombotic events in females, carriers of mutation of prothrombin gene [F2(20210)GA].
1 cl, 4 ex, 1 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF SEVERE PREECLAMPSIA IN PREGNANT WOMEN ACCOMPANYING A MUTATION OF THE PROTHROMBIN GENE, GENOTYPE F2G20210A | 2019 |
|
RU2723627C1 |
| METHOD FOR PREECLAMPSIA PREDICTION IN PREGNANT WOMEN WITH MUTATION OF FACTOR V LEIDEN 1691 GENE OF G/A AND A/A GENOTYPE | 2016 |
|
RU2636228C1 |
| METHOD FOR PREVENTION OF PREECLAMPSIA IN CARRIERS OF F2G20210A MUTATION WITH SUPERTHRESHOLD INCREASE OF PROTHROMBIN ACTIVITY | 2019 |
|
RU2712444C1 |
| METHOD FOR PREDICTION OF RISK OF DEGREE 2-3 CHRONIC PLACENTAL INSUFFICIENCY WITH FOETAL GROWTH DELAY SYNDROME IN PREGNANT WOMEN | 2013 |
|
RU2540928C1 |
| METHOD FOR PREDICTION OF RISK OF MALIGNANT GROWTHS IN FEMALE GENITAL ORGANS AND MAMMARY GLANDS | 2014 |
|
RU2578459C1 |
| METHOD FOR DIAGNOSING THROMBINEMIA IN PATIENTS WITH COVID-19 INFECTION | 2022 |
|
RU2794035C1 |
| METHOD FOR DETERMINING THE DURATION OF THROMBOPROPHYLAXIS WITH LOW-MOLECULAR-WEIGHT HEPARIN AFTER ABDOMINAL DELIVERY IN CARRIERS OF THE LEIDEN MUTATION, GENOTYPE F5 G1691A | 2020 |
|
RU2752776C1 |
| METHOD FOR DETERMINING HIGH THROMBOGENIC RISK IN PREGNANCY FOR HEPARIN PREVENTION | 2014 |
|
RU2564945C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING PREECLAMPSIA IN WOMEN BASED ON GENETIC MARKERS | 2022 |
|
RU2795660C1 |
| METHOD FOR PREDICTION OF CHORION SEPARATION IN FIRST TRIMESTER OF PREGNANCY | 2014 |
|
RU2566729C1 |
